| Dr Geoffrey Michael Smith, MD | |
|
15107 Vanowen St, Van Nuys, CA 91405-4542 | |
| (818) 782-6600 | |
| Not Available |
| Full Name | Dr Geoffrey Michael Smith |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 10 Years |
| Location | 15107 Vanowen St, Van Nuys, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144648056 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A148099 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sherman Oaks Hospital | Sherman oaks, CA | Hospital |
| Encino Hospital Medical Center | Encino, CA | Hospital |
| Valley Presbyterian Hospital | Van nuys, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sherman Oaks Emergency Medical Associates | 1557377736 | 16 |
| Valley Presbyterian Emergency Medical Associates | 1951308105 | 10 |
| Pacifica Emergency Medical Associates | 9436058971 | 12 |
News Archive
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
Sweet taste responses were enhanced by endocannabinoids in every case. The effect was specific for sweet taste, as endocannibinoids had no effect on responses to sour, salty, bitter or umami taste stimuli.
Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
› Verified 8 days ago
| Entity Name | Pacifica Emergency Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053350975 PECOS PAC ID: 9436058971 Enrollment ID: O20040712001555 |
News Archive
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
Sweet taste responses were enhanced by endocannabinoids in every case. The effect was specific for sweet taste, as endocannibinoids had no effect on responses to sour, salty, bitter or umami taste stimuli.
Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
› Verified 8 days ago
| Entity Name | Sherman Oaks Emergency Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518904150 PECOS PAC ID: 1557377736 Enrollment ID: O20060224000406 |
News Archive
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
Sweet taste responses were enhanced by endocannabinoids in every case. The effect was specific for sweet taste, as endocannibinoids had no effect on responses to sour, salty, bitter or umami taste stimuli.
Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
› Verified 8 days ago
| Entity Name | Valley Presbyterian Emergency Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033133103 PECOS PAC ID: 1951308105 Enrollment ID: O20061031000344 |
News Archive
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
Sweet taste responses were enhanced by endocannabinoids in every case. The effect was specific for sweet taste, as endocannibinoids had no effect on responses to sour, salty, bitter or umami taste stimuli.
Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
› Verified 8 days ago
| Entity Name | Centinela Freeman Emergency Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528333101 PECOS PAC ID: 0042469108 Enrollment ID: O20121004000437 |
News Archive
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
Sweet taste responses were enhanced by endocannabinoids in every case. The effect was specific for sweet taste, as endocannibinoids had no effect on responses to sour, salty, bitter or umami taste stimuli.
Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
› Verified 8 days ago
| Entity Name | Telemedicine365, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912525817 PECOS PAC ID: 0648683920 Enrollment ID: O20210105001789 |
News Archive
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
Sweet taste responses were enhanced by endocannabinoids in every case. The effect was specific for sweet taste, as endocannibinoids had no effect on responses to sour, salty, bitter or umami taste stimuli.
Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Geoffrey Michael Smith, MD 1550 Amherst Ave Apt 203, Los Angeles, CA 90025-3698 Ph: (818) 489-7519 | Dr Geoffrey Michael Smith, MD 15107 Vanowen St, Van Nuys, CA 91405-4542 Ph: (818) 782-6600 |
News Archive
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
Sweet taste responses were enhanced by endocannabinoids in every case. The effect was specific for sweet taste, as endocannibinoids had no effect on responses to sour, salty, bitter or umami taste stimuli.
Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
› Verified 8 days ago
Dr. Frank T. Gillingham, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 15107 Vanowen Street, Van Nuys, CA 91405 Phone: 818-902-2990 Fax: 818-904-3793 | |
Dr. Scott K Narimatsu, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 15107 Vanowen St, Van Nuys, CA 91405 Phone: 818-782-6600 | |
Dr. Thomas J. Lambert, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 15107 Vanowen Street, Van Nuys, CA 91405 Phone: 818-902-2990 Fax: 818-904-3793 | |
Dr. Homayoun Nassiri, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 15107 Vanowen St, Van Nuys, CA 91405 Phone: 818-902-2990 Fax: 818-904-3793 | |
Anna Trtchounian, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 15107 Vanowen St, Van Nuys, CA 91405 Phone: 818-782-6600 | |
Dr. Jonathan Lyons, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 15107 Vanowen St, Van Nuys, CA 91405 Phone: 818-782-6600 |